Loren Data's SAM Daily™

FBO DAILY ISSUE OF JUNE 11, 2004 FBO #0928
SOLICITATION NOTICE

68 -- Manufacture of Anthrax Therapeutics Products

Notice Date

6/9/2004
 

Notice Type

Solicitation Notice
 

NAICS

325414 — Biological Product (except Diagnostic) Manufacturing
 

Contracting Office

Department of Health and Human Services, Center for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, GA, 30341-4146
 

ZIP Code

30341-4146
 

Solicitation Number

2004-N-01385
 

Point of Contact

Vivian Hubbs, Contract Specialist, Phone (770) 488-2647, Fax (770) 488-2670, - Lorenzo Falgiano, Contract Specialist, Phone (770) 488-2629, Fax (770) 488-2670,
 

E-Mail Address

vdh6@cdc.gov, ljf5@cdc.gov
 

Description

The Department of Health and Human Services has a requirement for the acquisition and maintenance of therapeutic products for the Strategic National Stockpile (SNS) to treat U.S. civilians with inhalational anthrax disease. The types of products that may be acquired under this solicitation include immunotherapeutic antitoxin treatments, such as monoclonal antibodies and polyclonal antibody toxin inhibitors, human immune globulin and other protein therapeutic products such as mutated toxins, or small molecular entity treatments such as protease inhibitors for anthrax toxemia. It is anticipated that these products would be used in conjunction with antibiotics in the treatment of symptomatic patients exposed to anthrax. This requirement is for the initial acquisition of between 10,000 and 70,000 therapeutic courses of treatment for inhalational anthrax disease, potentially from a variety of product types, based on the availability of funds. The government reserves the right to make single or multiple contract awards. It is anticipated that additional requirements for anthrax therapeutic products from a variety of product types will be released approximately annually over the next two years, based on the availability of funds. The Office of Research and Development Coordination (ORDC) in OASPHEP has the primary responsibility within HHS to contract with industry for large-scale manufacturing and delivery of licensable products to the SNS in preparation for response to a public health emergency. Potential Offerors are required to have submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) by the time of proposal submission to be considered in response to this RFP. Potential Offerors? products must be allowed to proceed by FDA under IND at time of contract award. The requirement of the solicitation is that any successful Offeror will aggressively pursue FDA licensure or approval of their products. All lots of IND product purchased for the SNS through this acquisition are expected to qualify for licensure or product approval. This RFP is being issued on the basis of full and open competition. Subcontracting with small businesses is encouraged. All potential Offerors with a candidate product or products for the treatment of inhalational anthrax disease that meet the Absolute Criteria for Eligibility specified in the RFP are encouraged to submit a proposal in response to this solicitation. The Absolute Criteria for Eligibility will include: 1. A complete IND submitted to and received by the FDA for initiation of clinical trials. The IND must conform to the requirements as specified in 21 Code of Federal Regulations (CFR) 312. 2. Proof-of concept data in small animals. The anticipated period of performance will be for a total of five years or 60 months. Additional details and requirements will be described in the solicitation. The solicitation is scheduled to be released on or about Monday, June 28, 2004. Only written requests, directly from the requestor, for this solicitation will be accepted. Email requests will be accepted. No telephone requests will be accepted. Requests should reference the solicitation number, state the name of the firm, name of the requestor, mailing address, telephone number, fax number, and email address. The solicitation will also be posted to Fedbizopps. Requests should be mailed to Centers for Disease Control and Prevention, ATTN: Vivian S. Hubbs, 2920 Brandywine Road, Room 3209, Atlanta, GA 30341. Requests should be emailed to Vivian S. Hubbs at vdh6@cdc.gov. The applicable NAICS is 325414, Biological Product (except Diagnostic) Manufacturing , and the size standard is 500 employees.
 

Place of Performance

Address: Department of Health and Human Services Center for Disease Control and Prevention Atlanta, Georgia

Zip Code: 30333

Country: USA
 

Record

SN00600809-W 20040611/040609211807 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |